Get the Stockscreener App
71.86
1.14%
-0.83
Arcellx Inc stock is traded at $71.86, with a volume of 678.75K.
It is down -1.14% in the last 24 hours and down -20.28% over the past month.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$72.69
Open:
$72.93
24h Volume:
678.75K
Relative Volume:
0.87
Market Cap:
$4.16B
Revenue:
$76.81M
Net Income/Loss:
$-162.42M
P/E Ratio:
-24.03
EPS:
-2.99
Net Cash Flow:
$-122.49M
1W Performance:
+3.31%
1M Performance:
-20.28%
6M Performance:
+8.04%
1Y Performance:
-13.86%
1-Day Range:
$71.09
$73.94
1-Week Range:
$68.64
$79.75
52-Week Range:
$47.86
$94.07
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
71.86 | 4.20B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-16-25 | Initiated | Stifel | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
Arcellx Inc. (ACLX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment - Finviz
What Arcellx (ACLX)'s Anito‑cel Phase 2 Data Means For Shareholders - simplywall.st
Positive Outlook for Arcellx Inc: Buy Rating Backed by Strategic Positioning and Promising CAR T-cell Therapy - TipRanks
Stempoint Capital LP Has $13.27 Million Stock Position in Arcellx, Inc. $ACLX - MarketBeat
Stifel upgrades Arcellx stock, cites buying opportunity after share weakness By Investing.com - Investing.com South Africa
Stifel upgrades Arcellx stock, cites buying opportunity after share weakness - Investing.com
Cancer Study Buoys These Small Biotechs - Barron's
Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025 - ts2.tech
ASH 2025: Arcellx and Gilead’s Anito-cel challenges CAR-T market in R/R MM - Clinical Trials Arena
Arcellx Inc (ACLX) Receives a Buy from Canaccord Genuity - The Globe and Mail
Arcellx (ACLX) Valuation Check After Strong Phase 2 iMMagine-1 Results for Anito-cel in Multiple Myeloma - Sahm
Arcellx reports promising phase 2 study results - MSN
Arcellx Inc. Stock Surge: Time to Buy? - StocksToTrade
Arcellx Reports Promising Phase 2 Study Results - TipRanks
Arcellx, Inc. Announces Positive Data from iMMagine-1 Study - TradingView — Track All Markets
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $105 to $130 - 富途牛牛
Analyst Maintains 'Buy' Rating on Arcellx (ACLX) with Target Pri - GuruFocus
Arcellx (NASDAQ:ACLX) Given Buy Rating at Canaccord Genuity Group - MarketBeat
Why Is Arcellx Stock Surging Today? - Benzinga
Arcellx (NASDAQ:ACLX) Shares Gap UpShould You Buy? - MarketBeat
Arcellx shares jump on strong multiple myeloma trial results - MSN
Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Arcellx Inc - TipRanks
Arcellx stock soars after positive multiple myeloma therapy data By Investing.com - Investing.com UK
Arcellx (NASDAQ:ACLX) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Needham Reiterates Buy Rating for ACLX with $105 Price Target | - GuruFocus
Arcellx stock soars after positive multiple myeloma therapy data - Investing.com
Arcellx surges after promising data from mid-stage cancer therapy trial - TradingView — Track All Markets
Arcellx Says Phase 2 Cancer Study Shows 96% Overall Response Rate; Shares Up Pre-Bell - marketscreener.com
Arcellx Inc’s Anito-cel: Promising CAR-T Therapy with Superior Safety Profile and Market Readiness - TipRanks
Arcellx Inc’s Promising Future: Buy Rating Backed by Strong Efficacy, Safety, and Strategic Partnerships - TipRanks
Why Have Arcellx Inc Stocks Plummeted? - TipRanks
Arcellx Inc (NASDAQ:ACLX) Nasdaq Index Biotech Momentum - Kalkine Media
Assessing Arcellx (ACLX) Valuation Following Positive Pivotal CAR T Data and Commercial Launch Plans - Yahoo Finance
Optimistic Buy Rating for Arcellx Inc: Promising Anito-cel Therapy and Strategic Advancements - TipRanks
Arcellx Inc’s Promising iMMagine-1 Study and Strategic Plans Justify Buy Rating and $112 Price Target - TipRanks
Arcellx announces new data for its iMMagine-1 study in patients with RRMM - TipRanks
Trading the Move, Not the Narrative: (ACLX) Edition - news.stocktradersdaily.com
Arcellx (NASDAQ: ACLX) iMMagine-1 shows 96% ORR, 74% CR/sCR in Phase 2 RRMM - Stock Titan
Schroder Investment Management Group Acquires New Position in Arcellx, Inc. $ACLX - MarketBeat
Affinity Asset Advisors LLC Sells 35,000 Shares of Arcellx, Inc. $ACLX - MarketBeat
Arcellx (NASDAQ:ACLX) Stock Price Down 6.2%Here's Why - MarketBeat
Will Arcellx Inc. stock deliver shareholder valuePortfolio Value Report & Daily Stock Momentum Reports - Newser
Russell Investments Group Ltd. Decreases Holdings in Arcellx, Inc. $ACLX - MarketBeat
Decheng Capital LLC Has $36.06 Million Stake in Arcellx, Inc. $ACLX - MarketBeat
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting - MSN
Arcellx (ACLX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Setup Watch: Can Arcellx Inc stock continue upward trendJuly 2025 Intraday Action & Fast Moving Stock Trade Plans - BỘ NỘI VỤ
16,787 Shares in Arcellx, Inc. $ACLX Bought by XTX Topco Ltd - MarketBeat
Arcellx, Inc. $ACLX Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Arcellx, Inc. $ACLX Shares Acquired by American Century Companies Inc. - MarketBeat
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):